Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: A phase i study using a novel, adaptive bayesian dose-escalation model

Journal of Thoracic Oncology

Volumn 6, Issue 12, 2011, Pages 2120-2129

  Vansteenkiste, Johan ^a   Solomon, Benjamin ^b   Boyer, Michael ^c   Wolf, Jürgen ^d   Miller, Neil ^e   Di Scala, Lilla ^e   Pylvaenaeinen, Ilona ^e   Petrovic, Katarina ^e   Dimitrijevic, Sasa ^e   Anrys, Beatrijs ^a   Laack, Eckart ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c SYDNEY CANCER CENTRE   (Australia)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adaptive Bayesian dose escalation model; Everolimus; Non small cell lung cancer; Pemetrexed; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; EVEROLIMUS; PEMETREXED;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CATHETER INFECTION; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 81755184151     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182307ede     Document Type: Article

References (28)

1. D'Addario G, Felip E. Non-small cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):68-70.
2. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
3. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet 2009;373:1525-1531.
4. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-917.
5. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
7. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-1945. (Pubitemid 39071573)
8. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-2059. (Pubitemid 39534841)
9. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61: 3986-3997. (Pubitemid 32720961)
10. La Monica S, Galetti M, Alfieri RR, et al. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 2009;78:460-468.
11. O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-1595.
12. Papadimitrakopoulou V, Blumenschein GR, Leighl NB, et al.Aphase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): phase 1 results. J Clin Oncol 2008;26(20 Suppl):8051.
13. Soria J-C, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009;20:1674-1681.
14. Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003;66:431-438. (Pubitemid 36937028)
15. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-118. (Pubitemid 41002949)
16. O'Reilly T, Brandt R, Knohr F, et al. In vivo antitumor activity of RAD001 combined with Taxol®/carboplatinum or pemetrexed against human lung tumor xenograft models. Presented at the 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 12-16, 2008. Abstract 4007.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
18. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008;27:2439.
19. Cheung Y, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000;56:1177-1182.
20. Congdon P. Applied Bayesian Modelling (Wiley Series in Probability and Statistics). West Sussex, England: John Wiley & Sons Ltd, 2003.
21. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-380. (Pubitemid 29455582)
22. Clarke SJ, Boyer MJ, Millward M, et al. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 2005;49:401-412. (Pubitemid 41139154)
23. Di Scala L, Pylvänäinen I, Molloy B, et al. A novel Bayesian doseescalation phase I design investigating safety of combination of RAD001with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 2008:26(20 Suppl):1130.
24. Thall PF, Lee SJ. Practical model-based dose-finding in Phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer 2003;13:251-261. (Pubitemid 38222572)
25. ALIMTA [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company, 2009.
26. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008;372:449-456.
27. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
28. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263.